Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
robatumumab + irinotecan
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Robatumumab + irinotecan is an investigational combination therapy evaluated by Merck Sharp & Dohme for the treatment of advanced solid tumors. Robatumumab (SCH 717454, MK-7454) is a fully human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), inhibiting signaling pathways that drive tumor cell growth and survival. Irinotecan is a small molecule chemotherapy agent that inhibits DNA topoisomerase I, leading to double-strand DNA breaks and cell death. This combination was studied in a Phase 1B/2 trial (NCT00954512) in patients with colorectal adenocarcinoma, non-small cell lung cancer, gastric adenocarcinoma, breast cancer, renal cell carcinoma, and pancreatic adenocarcinoma. The trial was ultimately terminated, and development of the combination was discontinued.
- Brand names
- Camptosar
- Other names
- robatumumab + irinotecanSCH 717454 + irinotecanMK-7454 + irinotecanrobatumumab + FOLFIRI
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on robatumumab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on robatumumab + irinotecan.